In a First, a Drugmaker’s Lawsuit Challenges HRSA’s 340B Patient Definition

Why It Matters

A narrower patient definition could limit 340B discount eligibility, reducing savings for covered entities and increasing audit exposure for hospitals, while reshaping how the program is regulated post‑Chevron.

Key Takeaways

• AbbVie sues HRSA over 340B “patient” definition
• Seeks narrower definition to enable audits of covered entities
• Case follows 2024 Supreme Court decision limiting agency deference
• Potential tighter eligibility could cut hospitals’ 340B savings

Pulse Analysis

The 340B Drug Pricing Program, designed to stretch federal resources for safety‑net providers, hinges on a clear definition of who qualifies as a patient. AbbVie’s lawsuit targets HRSA’s 1996 guidance, which requires only minimal documentation of a patient’s interaction with a covered entity. By arguing that this guidance permits “diversion” of discounted drugs to individuals without recent or substantive care, AbbVie aims to force a statutory‑based definition that ties eligibility to direct, ongoing clinical encounters within the past year.

The legal backdrop is crucial. The Supreme Court’s 2024 ruling overturning Chevron deference signals that courts will now scrutinize agency interpretations more rigorously, favoring the plain text of statutes. AbbVie leverages this shift, contending that the 340B statute’s language—simply that drugs may not be sold to non‑patients—does not support HRSA’s expansive reading. This case therefore serves as a bellwether for how other health‑care regulations may be re‑examined in the post‑Chevron era, potentially prompting a wave of litigation aimed at tightening agency‑issued guidance across the sector.

If the court adopts AbbVie’s narrower view, covered entities could face heightened compliance burdens, including mandatory audits and possible repayment of discounts deemed improperly applied. The financial stakes are significant: 340B spending grew from roughly $6.6 billion in 2010 to nearly $44 billion in 2021, yet studies suggest many savings never reach patients. A stricter definition could shrink the pool of eligible prescriptions, altering hospital revenue models and prompting renegotiations with pharmaceutical manufacturers. Stakeholders should monitor the case closely, as its outcome may reshape the balance between drug‑maker interests, provider savings, and patient access under the 340B framework.